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Adenosine deaminase (ADA) deficiency leads to an accumulation of toxic purine degradation by-products, most
potently affecting lymphocytes, leading to adenosine deaminase-deficient severe combined immunodeficiency.
Whilst most notable affects are on lymphocytes, other manifestations include skeletal abnormalities,
neurodevelopmental affects and pulmonary manifestations associated with pulmonary-alveolar proteinosis. Affected
patients present in early infancy, usually with persistent infection, or with pulmonary insufficiency. Three treatment
options are currently available. Initial treatment with enzyme replacement therapy may alleviate acute symptoms
and enable partial immunological reconstitution, but treatment is life-long, immune reconstitution is incomplete,
and the reconstituted immune system may nullify the effects of the enzyme replacement. Hematopoietic stem cell
transplant has long been established as the treatment of choice, particularly where a matched sibling or well matched
unrelated donor is available. More recently, the use of gene addition techniques to correct the genetic defect in
autologous haematopoietic stem cells treatment has demonstrated immunological and clinical efficacy. This article
reviews the biology, clinical presentation, diagnosis and treatment of ADA-deficiency.
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Adenosine deaminase (ADA) is a key enzyme of the pur-
ine salvage pathways and deficiency caused by mutations
in the ADA gene results in one of the more common
causes of autosomal recessive severe combined immuno-
deficiency (SCID), accounting for approximately 10–15%
of cases in outbred populations [1]. Absent or impaired
ADA function leads to the accumulation of the toxic
metabolites adenosine, 2’deoxyadenosine and deoxyade-
nosine triphosphate (dATP). ADA-deficient SCID is
characterized by severe lymphocytopaenia affecting T-and
B-lymphocytes and NK cells, but, because of the ubiqui-
tous nature of the enzyme, non-immunological manifesta-
tions are also observed, including neurodevelopmental
deficits, sensorineural deafness and skeletal abnormalities.
The incidence of ADA-deficiency in Europe is estimated
to be between 1:375,000 to 1:660,000 live births [2]. Early
diagnosis of ADA-deficient SCID and initiation of treat-
ment is essential in this otherwise fatal condition. Current
treatment options include enzyme replacement therapy* Correspondence: andrew.gennery@ncl.ac.uk
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(HSCT), and autologous gene therapy (GT).Biochemistry
ADA is a ubiquitously expressed metabolic enzyme, al-
though level of enzyme activity varies, with highest levels
observed in lymphoid tissues, particularly the thymus,
the brain and gastrointestinal tract [2], and is expressed
both intracellularly and on the cell surface complexed with
CD26 [3]. With purine nucleoside phosphorylase, it forms
an essential component of the purine salvage pathway, re-
sponsible for the irreversible deamination of adenosine and
2’deoxyadenosine into inosine and 2’deoxyinosine respect-
ively. Absent or impaired function consequently results in
both intracellular and extracellular accumulation of
these substrates. Adenosine primarily derives from break-
down of adenosine triphosphate (ATP) and RNA, and
2’deoxyadenosine from breakdown of DNA. 2’deoxyadeno-
sine irreversibly inhibits the enzyme S-adenosylhomocysteine
(SAH) hydrolase causing accumulation of SAH, which
subsequently prevents S-adenosylmethionine-mediated
methylation processes required for normal thymocyte
differentiation, likely contributing to the impairment of
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followed by phosphorylation by deoxycytidine kinase
leads to accumulation of deoxyadenosine triphosphate
(dATP) which inhibits ribonucleotide reductase, prevent-
ing normal DNA synthesis and repair [5]. Adenosine is an
important extracellular signalling molecule; disruption of
these signalling pathways is thought to interfere with nor-
mal immune responses [6]. Adenosine receptors belong to
the family of G protein-coupled receptors, of which there
are four subtypes (A1, A2A, A2B and A3), which play differ-
ent roles in regulating normal cellular physiology in a wide
variety of tissues including the brain, cardiovascular
system and lungs [7].
Diagnosis
Diagnosis of ADA-deficiency is established by biochem-
ical and molecular genetic testing. Biochemical testing
demonstrates absent or greatly reduced ADA activity
(< 1% of normal) and marked elevation of the metabol-
ite dATP or total dAdo nucleotides (the sum of dAMP,
dADP and dATP) in erythrocytes. Reduced activity of
SAH hydrolase in erythrocytes (< 5% of normal) is also
characteristic [8]. If a patient with suspected ADA-
deficiency has had a recent blood transfusion, analysis
of ADA activity can be measured in the parents, with
reduced activity seen in heterozygous carriers, or can
be performed on non-erythroid cells such as leukocytes.
Fibroblasts can also be used, but fibroblast cultures are
usually not readily available and this may delay diagnosis.
Molecular genetic diagnosis relies on the identification of
bi-allelic pathogenic mutations in the ADA gene, located
on chromosome 20q12-q13.11 and in which over 70
causative mutations have been identified.
Supportive laboratory findings include lymphocytopae-
nia, with absence of T- and B-lymphocytes and NK cells
and low serum immunoglobulins, although in early infancy
IgG may be normal due to materno-placental transfer.
T-lymphocyte proliferative responses are low or absent,
as are specific antibody responses. The level of meta-
bolic substrates and the genotype have been shown to
correlate with the severity of the clinical phenotype [9].
Clinical manifestations
Immune-system - effects on a cellular level
The dominant consequences of ADA deficiency are on
the immune system, causing severe depletion of T- and
B-lymphocytes and NK cells, resulting in impaired cellu-
lar and humoral immunity. High levels of ADA are
expressed in lymphoid tissues due to the high levels of
cell turnover, particularly in the thymus, likely accounting
for the resulting severe lymphocytotoxic effects of defi-
ciency [10]. The underlying mechanisms responsible for
the deleterious effects on the immune system have been
elucidated with the use of ADA-deficient experimentalmodels. There are pronounced effects on thymocyte de-
velopment, although the precise stage at which this occurs
is unknown. Apasov et al. demonstrated extensive apop-
tosis in the thymi of ADA(−/−) murine models but not in
the peripheral lymph nodes and spleen, demonstrating the
detrimental effect on developing thymocytes. Apoptosis in
the thymi was evident predominantly at the cortico-
medullary junction and particularly affected double posi-
tive thymocytes. Peripheral T-lymphocytes were also ab-
normal, with aberrant distribution in secondary lymphoid
tissues and expression of cell markers, as well as defective
T-lymphocyte signaling through the TCR [11]. It is
thought that the combination of both intracellular accu-
mulation of toxic substrates and defective T-lymphocyte
signaling contribute to the depletion of developing
thymocytes.
The B-lymphocyte compartment is also affected in
ADA-deficiency with patients exhibiting severe B-
lymphocytopaenia and hypogammaglobulinaemia, although,
in contrast to T-lymphocytes, early B-lymphocyte de-
velopment does not appear to be disturbed [12]. Abnor-
mal splenic germinal centre architecture is observed
suggesting impaired antigen-dependent B-lymphocyte
maturation, and B-lymphocytes also displayed reduced
proliferative abilities, increased apoptosis and impaired
signaling upon activation [12]. This suggests that the B-
lymphocyte defect is more likely to be related to im-
paired differentiation due to an intrinsic defect rather
than solely due lack of appropriate CD4+ T-lymphocyte
help. Impaired V(D)J recombination due to increased
dATP levels may also negatively affect B-lymphocyte di-
versity and function [13].
Immune system - clinical manifestations
As a result of severely defected cellular and humoral im-
munity, the typical presentation of ADA-deficiency oc-
curs early in life with severe infections and failure to
thrive, and affected individuals will normally succumb
within the first or second year of life without intervention.
The clinical picture of ADA-deficient SCID is similar to
other genetic forms of SCID, with persistent diarrhoea,
dermatitis, and serious infections, often caused by oppor-
tunistic pathogens such as Pneumocystis jiroveci, being
characteristic. Physical findings include absent thymus
gland on thoracic-radiographs and absence of lymphoid
tissues.
Non-immune manifestations
The ubiquitous nature of ADA also means that conse-
quences of deficiency are not limited to lymphocytes,
and many other systemic non-immunological features
are also observed, with known impact on the nervous,
auditory, skeletal, pulmonary, hepatic and renal systems
as well as cognitive and behavioural abnormalities. Non-
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ent in recent years as survival and immune reconstitu-
tion improves following stem cell transplantation, and
awareness and identification of involvement of multiple
organ systems is essential to allow timely optimal
management.
Children with ADA-deficiency have been shown to
exhibit a range of behaviour abnormalities, including
attention deficits, hyperactivity, aggression and social
problems, which appear to develop independently of
the influences associated with HSCT [14, 15]. IQ levels
are lower in children with ADA-deficient SCID com-
pared to the population average and compared to chil-
dren with other forms of SCID [15]. High levels of
ADA expression found in the brain [10], and the find-
ing that the total IQ scores correlate with the level of
dATP at diagnosis [14], further support the theory that
cognitive impairment is both a consequence of the
metabolic disturbance in ADA-deficiency and dependent
on the degree of deficiency.
Bilateral sensorineural hearing loss was first reported
in two patients with ADA-deficiency who had been suc-
cessfully treated with HSCT. Structural and infectious
causes were excluded and both patients did not receive
any conditioning prior to HSCT, precluding that as a po-
tential cause and implicating the underlying metabolic
defect [16]. A high prevalence of bilateral sensorineural
hearing loss (58%) was reported in a cohort of 12 pa-
tients with ADA-deficiency who had been treated with
HSCT [17]. In this study, no relationship was found be-
tween deafness and dATP levels.
The metabolic role of adenosine deaminase and con-
sequences of toxic substrate accumulation in the lungs
has been demonstrated in experimental models, with
ADA(−/−)mice displaying severe pulmonary inflamma-
tion, with accumulation of activated macrophages and
eosinophils, and airway remodeling, reversible upon
initiation of ERT [5]. Mouse models have also shown
that prolonged exposure to high concentrations of ad-
enosine in the lung due to treatment with low dose
ERT leads to development of pulmonary fibrosis, but
these changes were reversed upon reducing pulmonary
adenosine levels [18]. In ADA-deficient patients, similar
pulmonary manifestations are seen, and non-infectious
pulmonary disease, including pneumonitis and pulmon-
ary alveolar proteinosisis (PAP), is found more fre-
quently than in other genetic forms of SCID [19]. 43.8%
of patients with ADA-deficient SCID had PAP in one
study that rapidly resolved (in all but one patient) fol-
lowing commencement of ERT [20].
Skeletal abnormalities such as involving the costochon-
dral joints are widely reported, possibly related to an im-
balance between nuclear factor-κB ligand (RANKL) and
osteoprotegerin (OPG), disturbing the interaction betweenosteoblasts and osteoclasts and subsequent bone forma-
tion, although abnormalities are mainly only apparent on
radiological imaging without dysmorphic consequences
[21–24]. The effect of toxic metabolites on bone marrow
may play a role in the ‘auto-conditioning’ evident in
ADA-deficient SCID, with the creation of stem cell
niches, facilitating donor hematopoietic stem cell engraft-
ment. However, skeletal abnormalities have also been
reported in other immunodeficiencies and complete
correction following therapy is not seen suggesting
other factors involved in the pathogenesis.
Hepatic involvement in ADA-deficiency appears to dif-
fer between mice and humans. Murine ADA(−/−)
models display severe hepatocellular degeneration that is
fatal in the perinatal period [25]. In comparison, a severe
degree of hepatic impairment is not normally seen in
ADA-deficient patients, although there is a case report
of a patient with ADA-deficient SCID who developed
rapid fatal hepatic failure which could not be attributed
to infection [26], and a neonate with ADA-deficient
SCID with hepatitis and hyperbilirubinaemia which re-
solved with ERT [27]. Reports of renal involvement in
ADA-deficiency include the occurrence of mesangial
sclerosis found in 7/8 autopsies of ADA-deficient patients,
with 6/8 also demonstrating cortical sclerosis of the ad-
renal glands [22]. Atypical haemolytic uraemic syndrome
was reported in 4 patients with ADA-deficiency, 2 who
recovered with mild or no residual renal impairment
following supportive management and initiation of ERT
[28]. Dermatofibrosarcoma protuberans is a rare malig-
nant skin tumour, which has been reported to occur
with greater frequency in patients with ADA-deficiency,
but the mechanism behind this is unclear [29].
While ADA-deficiency is widely accepted as a systemic
metabolic disorder, it is important to consider that cer-
tain systemic manifestations have only been reported in
a small number of patients. Other contributing factors
such as infectious agents may be involved and further
investigation into the underlying pathogenesis of these
manifestations is needed. Nevertheless, awareness of
multi-organ involvement is essential for optimal patient
care.
Partial and late onset ADA-deficiency
There is heterogeneity in the phenotype of ADA-
deficiency, with approximately 15–20% of patients exhibit-
ing a ‘delayed clinical onset’ presenting with less severe,
but gradually worsening, combined immune deficiency
later in life, usually within the first decade, but occasion-
ally in adulthood [8, 30, 31]. Clinical manifestations in this
‘delayed onset’ group include recurrent, but less severe
infections, particularly affecting the sinopulmonary tract.
Viral infections with papilloma virus also occur [32].
Autoimmunity, allergy and elevated IgE levels can also
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types it is important to consider the diagnosis of ADA-
deficiency in older individuals, as delay in recognition
leads to deterioration in immunological function and
the development of irreversible sequelae of recurrent
and chronic infections. Screening has also identified
asymptomatic individuals who have very low or absent
ADA activity in erythrocytes, but greater levels of ADA
activity (2%–50% of normal) in nucleated cells, so called
‘partial ADA-deficiency’ [33–37]. These patients have
seemingly normal immune function and life expectancy,
although long-term follow-up data is currently unavailable
to confirm this.
Management
Unlike other forms of SCID, management of ADA-
deficiency includes multiple options; ERT, allogeneic
HSCT, and autologous GT, of which only the latter two
are curative.
ERT with polyethylene glycol-conjugated adenosine
deaminase (PEG-ADA) is the one therapeutic option
that is not definitive in terms of disease correction but
allows systemic clearance or ‘detoxification’ of the toxic
metabolic substrates. ERT is an option if there is not a
suitable HSCT donor, or if there are contraindications to
HSCT, however, long-term ERT is associated with sub-
optimal immune reconstitution [38]. Other limitations
to ERT include lack of availability in some countries,
high cost and the fact that lifelong treatment is required.
It is also a short term option used as a stabilizing bridge
to HSCT or GT to improve endogenous immune function
and help in recovery from infections or in the setting of
pulmonary alveolar proteinosis to optimise clinical con-
dition prior to definitive therapy [39]. Use of ERT and
timing of cessation prior to allogeneic HSCT must be
carefully considered as improving recipient immunity
poses a potentially increased risk of graft rejection, but
cessation of ERT subjects the patient to a significantly
increased risk of infection. Interestingly, Hassan et al.
showed no difference in survival outcome between pa-
tients who did and did not receive ERT ≥ 3 months
prior to HSCT, but the majority of the group who re-
ceived ERT proceeded to have matched unrelated
donor/mismatched unrelated donor (MUD/MMUD)
or haploidentical donor transplants [40]. ERT may be
continued for one month following GT, or up to the
time of infusion, to maintain low levels of toxic
metabolites to facilitate engraftment of the gene-
corrected cells [39].
Traditionally, HSCT has been the treatment of choice
for ADA-deficient SCID, usually performed as soon as
possible following diagnosis to minimise the time exposed
to high levels of toxic metabolites and before acquisition
of infections. In the largest study to date examining theoutcome of 106 patients with ADA-deficient SCID fol-
lowing HSCT, earlier HSCT was associated with a bet-
ter overall survival but this did not reach statistical
significance, possibly due to smaller patient numbers in
the older groups [40]. A superior overall outcome is ob-
served following HSCT using matched sibling and family
donors (MSD/MFD) compared to MUD and haploidenti-
cal donors (86% and 81% versus 66% and 43% respect-
ively) [40]. This may be related to faster availability of
sibling or family donors, likely resulting in a better clinical
condition going into HSCT. MSD and MFD HSCTs are
also usually performed without serotherapy, impacting
positively on the rate of T-lymphocyte recovery and clear-
ance of viral infections in these patients. Outcome is also
significantly improved in non-conditioned HSCT com-
pared to myeloablative conditioning, although lack of con-
ditioning may also impair engraftment, particularly with
haploidentical donors [40]. Unconditioned HSCT using a
MSD or MFD is associated with successful cellular and
humoral immune reconstitution, although long-term out-
come of immune status is unknown and further follow-up
is necessary [40]. This is in contradisctinction to other
forms of SCID, and it may be that the local toxic effects of
ADA deficiency on the marrow act as ‘auto-conditioning’
and allow donor stem cell engraftment in the absence of
chemotherapy. Patients who survive HSCT appear to do
well in terms of immune reconstitution, regardless of what
type of donor was used, with most patients achieving
complete cellular and humoral recovery, are able to make
vaccine responses and do not require immunoglobulin re-
placement [40]. In contrast, only about 50% of patients on
long term ERT are able to discontinue immunoglobulin
replacement therapy.
Less than 25% of patients with ADA-deficient SCID
have a MSD or MFD available, and in such situations
GT has become established as an accepted therapeutic
option. Following initial development more than 20 years
ago [41–43], GT for ADA-deficient SCID has become a
milestone in medical advancement as the first European
Union (EU) licensed ex vivo stem cell retroviral vector
GT (Strimvelis™) [44, 45]. Initial approaches, prior to the
development of Strimvelis™, utilised bone marrow or
umbilical cord blood without preparative conditioning
but resulted in inadequate ADA production and patients
required ongoing ERT. Improvement of gene transfer
methods and the introduction of non-myeloablative con-
ditioning with low-dose busulfan prior to infusion to
make space for the transfected cells resulted in effective
immune reconstitution and, to date, no reports of geno-
toxic insertional mutagenesis [44, 46–48], in contradis-
tinction to other primary immunodeficiencies treated by
gene therapy using retroviral vectors [49–51]. The lar-
gest report to date by Cicalese et al. of 18 ADA-SCID
patients treated with GT, with a median follow-up of
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transformations, reduced rate of infections and robust
T-lymphocyte and later B- lymphocyte reconstitution,
although the percentage of gene-corrected myeloid
cells was much lower [44]. Advantages of GT include
the absence of graft-versus-host disease risk, and fas-
ter initiation of therapy compared to that involved
with a donor search when a MSD or MFD is not avail-
able. However, long-term outcome is not yet known
and further monitoring is required to allow better un-
derstanding of the risks associated with GT compared
to allogeneic HSCT or long term ERT. Although GT
using gamma-retroviral vectors has demonstrated an
excellent safety profile to date, new developments
using lentiviral vector-mediated GT, which harnesses
the potential to transduce both non-dividing and div-
iding cells, have been recently reported which display
promising results in terms of both clinical efficacy and
safety [52–54].
Long term outcome
Transplantation using a MSD or MFD without condi-
tioning early after diagnosis is associated with a good
outcome in terms of survival and CD3+ recovery in the
first year post HSCT [40], but little is known about the
long term outcome and quality of immune reconstitu-
tion of patients with ADA-deficient SCID. Extended ap-
plication of newborn screening for SCID may contribute
to improving outcomes moreover in the future by allow-
ing identification of infants with SCID (of all genetic
causes) before the development of infections and other
complications using the detection of T-cell receptor ex-
cision circles (TRECs). TRECs are pieces of DNA excised
during development of the T-cell receptor, and are an ac-
curate measure of thymic output. Patients with SCID have
a significantly decreased number of TRECs which can be
detected using the newborn dried blood spot [55]. Earlier
diagnosis and a reduced burden of complications allows
for more prompt intervention and improved outcome as
studies indicate that siblings diagnosed based on a known
family history have a significantly improved survival [56].
Despite the positive outlook in terms of immune reconsti-
tution following HSCT as reported by Hassan et al., the
follow-up period in this study was a maximum of 27.
6 years (median 6.5 years) [40], and longer follow-up data
are required to continue to evaluate the permanency of
T-lymphocyte immunity, as initial data suggests that
thymopoiesis is limited in unconditioned MFD/MSD
HSCTs, which may lead to eventual exhaustion of the
T-lymphocyte repertoire [40]. The prospects of GT as a
therapeutic option are also promising; particularly with
the development of refined vectors and gene editing
technology, but further long term follow-up monitoring
is needed. Development is also taking place in theimprovement of PEG-ADA, with a clinical trial ongoing
utilising a recombinant source enzyme as an alternative
to the currently used bovine sequences [54]. Although
no large prospective studies have been performed examin-
ing the outcome of non-immunological defects following
definitive treatment, retrospective small reports suggest
that neurological, behavioural and audiological defects are
not corrected. Further studies are needed to examine if
factors such as donor type and conditioning regimen, or
type of therapy, influence outcomes in these areas. Further
understanding is also needed of the underlying pathogen-
esis involved in the non-immune systemic manifestations
to allow optimal investigation and management as well as
to fully decipher between the metabolic effects of ADA-
deficiency and effects inflicted by infectious agents.
Conclusion
The ubiquitous expression of ADA means that deficiency
can lead to a complex systemic metabolic disorder with
multiple organ involvement with potential to cause signifi-
cant morbidity unrelated to the immunodeficiency. Fur-
ther understanding of non-immune manifestations is
required. Early definitive therapy with HSCT using a MSD
or MFD results in a good overall outcome, and GT is now
an accepted therapeutic option for those without a suit-
able donor. The long term outcome of patients regardless
of the type of therapy given is unknown and further moni-
toring is needed.
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